Ionis Pharmaceuticals Inc (LTS:0JDI) Stock Price, Trades & News

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Financial Strength

4/10

Name	Current	Vs Industry
Cash-To-Debt	0.94
Equity-to-Asset	0.14
Debt-to-Equity	4.15
Debt-to-EBITDA	-9.4
Piotroski F-Score	2/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.64	Distress Grey Safe
Beneish M-Score	-1.28	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	12.5
	3-Year EBITDA Growth Rate	-2
	3-Year EPS without NRI Growth Rate	-0.9
	3-Year FCF Growth Rate	0.7
	3-Year Book Growth Rate	-9.4
	Future 3-5Y Total Revenue Growth Rate Estimate	32.78

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	12.89
	9-Day RSI	20.08
	14-Day RSI	25.21
	3-1 Month Momentum %	-4.43
	6-1 Month Momentum %	-9.63
	12-1 Month Momentum %	74.79

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	4.1
	Quick Ratio	4.09
	Cash Ratio	2.68
	Days Inventory	192.72
	Days Payable	454.81

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-4.8
	Shareholder Yield %	-6.1

Profitability Rank

2/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	98.35
	Operating Margin %	-33.29
	Net Margin %	-30.9
	EBITDA Margin %	-20.52
	FCF Margin %	-92.4
	OCF Margin %	-86.06
	ROE %	-60.42
	ROA %	-10.34
	ROIC %	-31.52
	3-Year ROIIC %	4.07
	ROC (Joel Greenblatt) %	-52.92
	ROCE %	-9.87
	Years of Profitability over Past 10-Year	3
	Moat Score	5
	Tariff Resilience Score	7

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	9.15
	PB Ratio	19.16
	Price-to-Tangible-Book	19.19
	EV-to-EBIT	-39.28
	EV-to-Forward-EBIT	-15.12
	EV-to-EBITDA	-43.75
	EV-to-Forward-EBITDA	-15.69
	EV-to-Revenue	8.98
	EV-to-Forward-Revenue	10.69
	EV-to-FCF	-9.72
	Price-to-GF-Value	1.06
	Price-to-Median-PS-Value	0.91
	Earnings Yield (Greenblatt) %	-2.55
	FCF Yield %	-10.43

Financials (Next Earnings Date:2026-07-30 Est.)

Annual Quarterly TTM

LTS:0JDI's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Ionis Pharmaceuticals Inc Executives

Details

GF Value™: $53.91

LTS:0JDI

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 5 Severe warning signs with 0JDI. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	1,058.189
	EPS (TTM) ($)	-2.07
	Beta	0.4268
	3-Year Sharpe Ratio	0.6
	3-Year Sortino Ratio	1.47
	Volatility %	54.91
	14-Day RSI	25.21
	14-Day ATR ($)	3.990265
	20-Day SMA ($)	76.055545
	12-1 Month Momentum %	74.79
	52-Week Range ($)	40.24 - 86.74
	Shares Outstanding (Mil)	165.26

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	2
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Ionis Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Ionis Pharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings conference call for 2026	2026-10-29 11:30	In 108 days
Third quarter earnings results for 2026	2026-10-29	In 107 days
Second quarter earnings conference call for 2026	2026-07-30 11:30	In 17 days
Second quarter earnings results for 2026	2026-07-30	In 16 days
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-10 08:40	74.57 (+1.32%)
General meeting for 2026	2026-06-04 14:00	73.83 (+0.31%)
Guidance call for 2026	2026-05-19 08:30	72.42 (-2.77%)
Guidance call for 2026	2026-05-12 13:40	75.91 (-0.77%)
First quarter earnings conference call for 2026	2026-04-29 08:30	71.48 (-2.59%)
First quarter earnings results for 2026	2026-04-29	71.48 (-2.59%)

Show

Entries

Ionis Pharmaceuticals Inc Frequently Asked Questions

What is Ionis Pharmaceuticals Inc(LTS:0JDI)'s stock price today?

The current price of LTS:0JDI is $56.98. The 52 week high of LTS:0JDI is $86.74 and 52 week low is $40.24.

When is next earnings date of Ionis Pharmaceuticals Inc(LTS:0JDI)?

The next earnings date of Ionis Pharmaceuticals Inc(LTS:0JDI) is 2026-07-30 Est..

Does Ionis Pharmaceuticals Inc(LTS:0JDI) pay dividends? If so, how much?

Ionis Pharmaceuticals Inc(LTS:0JDI) does not pay dividend.

Press Release

	Subject	Date
	Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease	2026-07-14
	IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)	2026-07-13
	Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome	2026-07-13
	IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals	2026-07-10
	Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)	2026-07-09
	Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy	2026-07-09
	Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome	2026-07-06
	Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.	2026-06-25
	TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)	2026-06-24
	Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors	2026-06-08

10/Page

Articles on Ionis Pharmaceuticals Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.